We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
In what could become a competitive bidding situation, Sanofi-Aventis has announced its offer to acquire the remaining 75% of Czech generic drug maker Zentiva that it does not already own for €43.42 per share, or about €1.24bn ($1.9bn). The offer comes on the heels of a bid proposed in May by Czech financial institution PPF, Zentiva's second largest shareholder (to Sanofi) for €39 per share. (Zentiva's board has recommended that shareholders not accept PPF's initial offer.)
Deal Industry
Pharmaceuticals
Pharmaceuticals
Generic Drugs
Nutraceuticals
OTC, Consumer
Deal Status
Final
Deal Type
Acquisition
Partial Acquisition
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?